ID   IMR-5rCDDP1000
AC   CVCL_RR56
DR   Wikidata; Q54897652
RX   PubMed=24466371;
RX   PubMed=31581737;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): PubMed=31581737
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9
ST   D16S539: 8
ST   D18S51: 12
ST   D19S433: 14,15
ST   D21S11: 30,31
ST   D2S1338: 23,24
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,12
ST   Penta E: 7,15
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1306 ! IMR-5
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 7
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=31581737; DOI=10.3390/cells8101194;
RA   Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R.,
RA   Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M.,
RA   Michaelis M.;
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
//